Morales SA

Language: Spanish
References: 22
Page: 75-78
PDF size: 88.73 Kb.

Text Extraction

No abstract.

REFERENCES

1. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010 ; 9 (5): 469-80.

2. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012 ; 308 (13): 1340-9.

3. Wiysonge CS, Opie LH. β-Blockers as initial therapy for hypertension. JAMA. 2013 ; 310 (17): 1851-2.

4. Morales Salinas A. Atenolol in uncomplicated hypertension: time for changes. Lancet Neurol. 2010 ; 9 (7): 652.

5. Morales Salinas A, Coca A. The B-blockers Crumbling Continues?: A critical analysis of the REACH registry. The Ochsner journal. 2013 ; 13 (1): 167.

6. Morales Salinas A. Polémica con la utilidad de los beta-bloqueadores en prevención secundaria: análisis crítico del registro REACH. Finlay. 2013 ; 3 (2): 1-5.

7. Morales Salinas A. Los betabloqueadores como primera opción del tratamiento en la hipertensión no complicada: ¿posible o no?. Finlay. 2011 ; 1 (1): 53-6.

8. Morales Salinas A. Variabilidad en la medida de la presión arterial periférica. ¿Limitación o marcador de riesgo?. Hipertens Riesgo Vasc. 2012 ; 29 (2): 50-1.

9. Morales Salinas A. Dogmas y actualidades del uso de los beta-bloqueadores en prevención secundaria. Segunda parte. Finlay. 2012 ; 2 (1): 1-2.

10. Morales Salinas A. Dogmas y actualidades del uso de los beta-bloqueadores en prevención secundaria. Primera parte. Finlay. 2011 ; 1 (2): 1-3.

11. James PA, Oparil S, Carter BL, Cushman WC Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013 ; doi:10.1001/jama.2013.284427:

12. Morales Salinas A, Martínez C, Pérez JR. Guías de hipertensión arterial. Novedad y polémica. Medicentro. 2004 ; 8 (3): 1-3.

13. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013 ; 34 (28): 2159-219.

14. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical Practice Guidelines for the Management of Hypertension in the Community: a Statement by the American Society of Hypertension and the International Society of Hypertension. Hypertension. 2013 ; doi: 10.1111/jch.12237:

15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 ; 289 (19): 2560-72.

16. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 ; 359 (9311): 995-1003.

17. Vanhoutte PM, Gao Y. β-Blockers, nitric oxide, and cardiovascular disease. Curr Opin Pharmacol. 2013 ; 13 (2): 265-73.

18. Neutel JM, Schnaper H, Cheung DG, Graettinger WF, Weber MA. Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J. 1990 ; 120 (1): 166-71.

19. McGill JB. Optimal use of β-blockers in high-risk hypertension: a guide to dosing equivalence. Vas Health Risk Manag. 2010 ; 6 (1): 363-72.

20. Flack JM, Nasser SA. Benefits of once-daily therapies in the treatment of hypertension. Vas Health Risk Manag. 2011 ; 7: 777-87. doi: 10.2147/VHRM.S17207.

21. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006 ; 174 (12): 1737-42.

22. Joshi R, Jan S, Wu Y, Mac Mahon S. Global inequalities in access to cardiovascular health care: our greatest challenge. J Am Coll Cardiol. 2008 ; 52 (23): 1817-25.